Ulf Dettmer

Dr. Ulf Dettmer

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Molecular Cell
Verified
Journal Article
Closed access
SFSaranna Fanning
Saranna Fanning
AHAftabul Haque
Aftabul Haque
TIthibaut imberdis
thibaut imberdis
VBValeriya Baru
Valeriya Baru
MBM. Inmaculada Barrasa
M. Inmaculada Barrasa
DSDennis Selkoe
Dennis Selkoe

3 January 2020 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
SFSaranna Fanning
Saranna Fanning
DSDennis Selkoe
Dennis Selkoe
UDUlf Dettmer
Ulf Dettmer
Lipids play a more significant role in Parkinson’s disease and its related brain disorders than is currently recognized, supporting a “lipid cascade”. The 14 kDa protein α-synuclein (αS) is strongly associated with Parkinson’s disease (PD), dementia with Lewy bodies (DLB), other synucleinopathies such as multiple system atrophy, and even certain forms of Alzheimer’s disease. Rigorously deciphering the biochemistry of αS in native systems is the key to developing treatments. αS is highly expressed in the brain, the second most lipid-rich organ, and has been proposed to be a lipid-binding protein that physiologically interacts with phospholipids and fatty acids (FAs). αS-rich cytoplasmic inclusions called Lewy bodies and Lewy neurites are the hallmark lesions of synucleinopathies. Excess αS–membrane interactions may trigger proteinaceous αS aggregation by stimulating its primary nucleation. However, αS may also exert its toxicity prior to or independent of its self-aggregation, e.g., via excessive membrane interactions, which may be promoted by certain lipids and FAs. A complex αS-lipid landscape exists, which comprises both physiological and pathological states of αS. As novel insights about the composition of Lewy lesions occur, new lipid-related PD drug candidates emerge, and genome-wide association studies (GWAS) increasingly validate new hits in lipid-associated pathways, it seems timely to review our current knowledge of lipids in PD and consider the roles for these pathways in synucleinopathies.

16 January 2023 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
NRNagendran Ramalingam
Nagendran Ramalingam
SJShan-Xue Jin
Shan-Xue Jin
TMTim E. Moors
Tim E. Moors
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
KSKazuma Shimanaka
Kazuma Shimanaka
UDUlf Dettmer
Ulf Dettmer
In Parkinson’s disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4 h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent α-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound α-synuclein. Patch clamping of rat SNCA−/− neurons expressing exogenous wild-type or phospho-incompetent (S129A) α-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129AKI) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of α-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.

19 June 2017 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
UDUlf Dettmer
Ulf Dettmer
NRNagendran Ramalingam
Nagendran Ramalingam
VSVictoria E. von Saucken
Victoria E. von Saucken
TKTae-Eun Kim
Tae-Eun Kim
ANAndrew J. Newman
Andrew J. Newman
DSDennis Selkoe
Dennis Selkoe
α-Synuclein (αS) forms round cytoplasmic inclusions in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Evidence suggests a physiological function of αS in vesicle trafficking and release. In contrast to earlier tenets, recent work indicates that αS normally exists in cells in a dynamic equilibrium between monomers and tetramers/multimers. We engineered αS mutants incapable of multimerization, leading to excess monomers at vesicle membranes. By EM, such mutants induced prominent vesicle clustering, leading to round cytoplasmic inclusions. Immunogold labeling revealed abundant αS intimately associated with vesicles of varied size. Fluorescence microscopy with marker proteins showed that the αS-associated vesicles were of diverse endocytic and secretory origin. An αS ‘3K’ mutant (E35K + E46K + E61K) that amplifies the PD/DLB-causing E46K mutation induced αS-rich vesicle clusters resembling the vesicle-rich areas of Lewy bodies, supporting pathogenic relevance. Mechanistically, E46K can increase αS vesicle binding via membrane-induced amphipathic helix formation, and ‘3K’ further enhances this effect. Another engineered αS variant added hydrophobicity to the hydrophobic half of αS helices, thereby stabilizing αS-membrane interactions. Importantly, substituting charged for uncharged residues within the hydrophobic half of the stabilized helix not only reversed the strong membrane interaction of the multimer-abolishing αS variant but also restored multimerization and prevented the aberrant vesicle interactions. Thus, reversible αS amphipathic helix formation and dynamic multimerization regulate a normal function of αS at vesicles, and abrogating multimers has pathogenic consequences.

23 September 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TIthibaut imberdis
thibaut imberdis
JNJoseph Negri
Joseph Negri
NRNagendran Ramalingam
Nagendran Ramalingam
ETElizabeth Terry-Kantor
Elizabeth Terry-Kantor
GHGary P. H. Ho
Gary P. H. Ho
UDUlf Dettmer
Ulf Dettmer
Significance: Misfolding and accumulation of the protein α-synuclein (αS) inside nerve cells characterize Parkinson’s disease (PD) and related brain diseases, for which no disease-modifying therapies exist. Robust cell models are needed that recapitulate abnormal αS folding/accumulation in real time, especially for compound screening. We took advantage of the engineered αS “3K” (E35K+E46K+E61K) mutation, which amplifies the familial PD-causing E46K and readily forms round inclusions. We rescued the inclusions with known αS modulators and then screened a ∼2,000-compound library. We identified the potential therapeutic target stearoyl-CoA desaturase; its inhibition cleared αS inclusions, in accord with the effects of conditioning in saturated fatty acids. We propose a model for how fatty acids serve as key modulators of cellular αS homeostasis.

30 June 2020 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
SFSaranna Fanning
Saranna Fanning
DSDennis Selkoe
Dennis Selkoe
UDUlf Dettmer
Ulf Dettmer